• Sepsis, 3rd cause of death in the world, worsened by the spread of bacterial infections with global warming and by the aging of the population
• No effective therapeutic option against sepsis available to date
• ABIONYX’s innovative approach by restoring the level of apoA-1 protein in the human body to eliminate endotoxins, allows the patient to better fight against sepsis
• Positive clinical results from the 2a RACERS study for the treatment of sepsis will be detailed in an upcoming scientific publication by the end of 2023
Toulouse, FRANCE, Lakeland MI, USA, September 12, 2023, at 8:00 p.m. – ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible), a new generation biotechnology company dedicated to the discovery and development of innovative therapies based on the sole natural recombinant apolipoprotein apoA-1 in the world, looks back on its commitment and strategic analysis for the development of its innovative breakthrough treatment on the occasion of World Sepsis Day.
To receive information from ABIONYX Pharma in real time, send a request to [email protected].